Guest Editors
Prof. Hooman Yarmohammadi
Email: yarmohah@mskcc.org
Affiliation: Department of Radiology, Memorial Sloan Kettering Cancer Center, 10065, New York, United States
Homepage:
Research Interests: Liver cancer and conditions
Liver metastases
Gallbladder cancer
Pancreatic cancer and conditions
Lung cancer
Summary
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, with rising incidence rates linked to liver diseases such as cirrhosis and viral hepatitis. Despite advances in diagnosis and management, effective treatment options remain limited, and the prognosis for advanced HCC patients is still poor.
This special issue aims to highlight recent developments in the treatment of HCC, including novel therapeutic agents, combination therapies, and personalized medicine approaches. Topics of interest include targeted therapies, immune checkpoint inhibitors, gene therapy, and the role of biomarkers in predicting treatment responses. Additionally, the issue will explore new perspectives on surgical, radiological, and interventional treatments. We invite original research, clinical trials, and reviews that offer insights into the future directions of HCC therapy, with the goal of improving patient outcomes and quality of life.
Keywords
Hepatocellular carcinoma (HCC), Targeted therapies, Immune checkpoint inhibitors, Personalized medicine, Liver cancer treatment, Clinical trials
Login
Register
Submit a Paper
Propose a Special lssue